The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Nature Reviews Clinical Oncology · 2025-02 · 22 (2) · 95-116
DOI: 10.1038/s41571-024-00971-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Reviews Clinical Oncology, online erschienen am 29.11.2024. Verfasst von Fei Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 212-mal zitiert (Crossref) und nennt 277 Literaturangaben.
Abstract (Originalsprache)
The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, which are often characterized by potent central nervous system penetrance, are the standard-of-care first-line treatment for advanced-stage EGFR-mutant NSCLC. Rational combinations of third-generation EGFR TKIs with anti-angiogenic drugs, chemotherapy, the EGFR-MET bispecific antibody amivantamab or local tumour ablation are being investigated as strategies to delay drug resistance and increase clinical benefit. Furthermore, EGFR TKIs are being evaluated in patients with early stage or locally advanced EGFR-mutant NSCLC, with the ambitious aim of achieving cancer cure. Despite the inevitable challenge of acquired resistance, emerging treatments such as new TKIs, antibody-drug conjugates, new immunotherapeutic approaches and targeted protein degraders have shown considerable promise in patients with progression of EGFR-mutant NSCLC on or after treatment with EGFR TKIs. In this Review, we describe the current first-line treatment options for EGFR-mutant NSCLC, provide an overview of the mechanisms of acquired resistance to third-generation EGFR TKIs and explore novel promising treatment strategies. We also highlight potential avenues for future research that are aimed at improving the survival outcomes of patients with this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
- Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
- Division of Medical Oncology, National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, Singapore.
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA.
- Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. caicunzhoudr@163.com.
Zitieren
APA
Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2025). The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nature Reviews Clinical Oncology, 22(2), 95-116. https://doi.org/10.1038/s41571-024-00971-2
Vancouver
Zhou F, Guo H, Xia Y, Le X, Tan DSW, Ramalingam SS, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nature Reviews Clinical Oncology. 2025;22(2):95-116. doi:10.1038/s41571-024-00971-2
BibTeX
@article{Zhou2025,
author = {Zhou, Fei and Guo, Haoyue and Xia, Yang and Le, Xiuning and Tan, Daniel S W and Ramalingam, Suresh S and Zhou, Caicun},
title = {The changing treatment landscape of EGFR-mutant non-small-cell lung cancer},
journal = {Nature Reviews Clinical Oncology},
year = {2025},
volume = {22},
number = {2},
pages = {95--116},
doi = {10.1038/s41571-024-00971-2}
}
EUVIMED